4.69
+0.02(+0.43%)
Currency In USD
| Previous Close | 4.67 |
| Open | 4.55 |
| Day High | 4.72 |
| Day Low | 4.49 |
| 52-Week High | 5.1 |
| 52-Week Low | 2.71 |
| Volume | 1.59M |
| Average Volume | 1.61M |
| Market Cap | 902M |
| PE | -20.39 |
| EPS | -0.23 |
| Moving Average 50 Days | 4.39 |
| Moving Average 200 Days | 4.01 |
| Change | 0.02 |
If you invested $1000 in Arbutus Biopharma Corporation (ABUS) 10 years ago, it would be worth $1,306.41 as of March 03, 2026 at a share price of $4.69. Whereas If you bought $1000 worth of Arbutus Biopharma Corporation (ABUS) shares 5 years ago, it would be worth $1,288.46 as of March 03, 2026 at a share price of $4.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
GlobeNewswire Inc.
3 hours ago
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed pate
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
GlobeNewswire Inc.
Jun 25, 2025 11:30 AM GMT
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2